Testing INV-6452 for advanced breast cancer and solid tumors
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced or metastatic cancer (spread beyond original site) confirmed by biopsy, with measurable tumors
- Cancer progressed after standard treatment, or you cannot tolerate standard options
- Good overall health and life expectancy greater than 3 months (ECOG score 0–1)
- Normal blood counts, liver, and kidney function
- Willing to provide tumor tissue sample or accept a pre-treatment biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This Phase 1 trial studies INV-1120 alone and with pembrolizumab (an immune therapy) in adults with advanced solid tumors that have stopped responding to standard treatment or have no standard option. The goal is to see how the treatments work, what dose is safest, and what side effects may occur.
This trial tests a new drug called INV-9956 in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It aims to see if the drug is safe and effective.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.